The Problems With Generic Medications Go Deeper Than One Company

Sharp health-economics explainer sparked by Turing/Daraprim's 5000% hike on a 50-year-off-patent drug. Beyond Vox's 'market too small,' Scott identifies the FDA bioequivalence-study barrier (~$2M + 2-3 years + legal fees for an ANDA -> 'go big or go home,' so nobody competes), contrasted with Longecity group-buys and the modafinil gap ($60 from ModafinilCat vs $469-850 at pharmacies). Then the Unapproved Drugs Initiative (2006) disaster -- companies grab a public-domain drug out of the commons by doing an FDA study and monopolize it (colchicine, an ancient gout remedy, hiked 5000%). And generic price dispersion even with competition (Celexa $4 vs $88 across pharmacies; the GoodRx price-drop-on-comparison; the insurance-copay explanation).

Quality 73 · Strong. A strong, informative, genuinely useful policy explainer with real insight into the regulatory dysfunction (the bioequivalence barrier; the Unapproved-Drugs-Initiative scandal; price dispersion) and concrete examples. Strong.

Claude’s paradigm shift 52 · Moderate. Moderate. Goes meaningfully beyond the standard 'market too small' account; a clarifying synthesis rather than a new paradigm.

Real-world impact 3 · Moderate. A sharp health-economics explainer of why generic-drug competition fails (the ~$2M FDA bioequivalence barrier; the Unapproved Drugs Initiative grabbing public-domain drugs out of the commons), with concrete examples. Real topical relevance to drug-pricing policy, but a diagnosis informing the debate — modest RWI.